ArticleCureus2026
A Comprehensive Pan-Cancer Analysis Revealing IGF2 Gene as a Diagnostic and Prognostic Biomarker.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer, one of the leading causes of mortality worldwide, is driven by genetic alterations promoting uncontrolled cell growth and metastasis. Among these genetic players, the insulin-like growth factor 2 (IGF2) gene has emerged as a significant factor in tumorigenesis. IGF2, a growth factor primarily produced in the liver, interacts with insulin and IGF receptors, influencing cell proliferation and survival. IGF2 is a known driver in fetal development and specific hepatic malignancies; its multi-omic diagnostic, prognostic, and immunological landscapes across diverse tissue barriers remain unmapped. This study presents a comprehensive pan-cancer analysis to systematically define the biomarker potential and epigenetic regulation of IGF2 across multiple human cancers.
methodsWe utilized various bioinformatic platforms, including Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN, and cBioPortal, to assess IGF2 gene expression and mutation profiles. Immune infiltration analysis evaluated IGF2's role in tumor-immune interactions. Gene expression data from the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were analyzed, and findings were validated using the Gene Expression Omnibus (GEO). Kaplan-Meier survival analysis was applied to investigate the correlation between IGF2 expression and overall survival in different cancers.
resultsIGF2 was significantly upregulated in cholangiocarcinoma (CHOL), liver hepatocellular carcinoma (LIHC), kidney chromophobe (KICH), and stomach adenocarcinoma (STAD) with P-values of 3.72E-05, 3.30-E08, 1.60E-03, and 1.43E-04, respectively. Survival analysis revealed that elevated IGF2 expression was associated with good prognosis in kidney renal papillary cell carcinoma (KIRP) (P = 7.2E-05). Immune infiltration analysis demonstrated a significant correlation between IGF2 expression and the presence of macrophages and CD4+ T cells in STAD (P = 1.30E-10, 2.61E-06, respectively), suggesting a role in modulating the tumor immune microenvironment. Genetic alterations in IGF2 were observed in multiple cancers, with missense mutations and deep deletions being the most prevalent. Patients with IGF2 mutations showed a trend toward poorer survival outcomes compared to those without mutations; however, the difference was not statistically significant (P = 0.384).
conclusionThis study revealed that IGF2 plays a potential role as a diagnostic biomarker for CHOL, KICH, LIHC, and STAD and a prognostic biomarker role in KIRP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.